ethyl 4-chloro-3-methylthieno[3,2-c]pyridine-7-carboxylate | 869543-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: ethyl 4-chloro-3-methylthieno[3,2-c]pyridine-7-carboxylate
• 英文别名: 4-chloro-3-methyl-thieno[3,2-c]pyridine-7-carboxylic acid ethyl ester
• CAS: 869543-47-5
• 化学式: C₁₁H₁₀ClNO₂S
• 分子量: 255.725
• InChiKey: OGGMPOZTPMKXCG-UHFFFAOYSA-N

物化性质

• 沸点：
  365.0±37.0 °C(Predicted)
• 密度：
  1.353±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-chloro-3-methylthieno[3,2-c]pyridine-7-carboxylate 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 反应 24.0h， 以84%的产率得到3-bromomethyl-4-chloro-thieno[3,2-c]pyridine-7-carboxylic acid ethyl ester
  参考文献：
  名称：

  4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides

  摘要：

  本文披露了一种新颖的4-氨基噻吩[3,2-c]吡啶-7-羧酸酰胺，以及它们的药用盐和酯，这些化合物是KDR和/或FGFR激酶的选择性抑制剂。这些化合物及其药用盐是抗增殖剂，可用于治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺的实体癌性肿瘤。还披露了含有这些化合物的药物组合物和使用这些化合物治疗癌症的方法。

  公开号：

  US20050256154A1
• 作为产物：
  描述：

  3-methyl-4-oxo-4,5-dihydro-thieno[3,2-c]pyridine-7-carboxylic acid ethyl ester 在 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 三氯氧磷 作用下， 反应 1.0h， 以60%的产率得到ethyl 4-chloro-3-methylthieno[3,2-c]pyridine-7-carboxylate
  参考文献：
  名称：

  4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives

  摘要：

  本发明涉及公式化合物、含有它们的药物以及将这些化合物用作药用活性剂的用途。这些化合物表现出作为Raf激酶抑制剂的活性，因此可能对通过该激酶介导的疾病的治疗有用，特别是作为抗癌剂。

  公开号：

  US20070060607A1

文献信息

• 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
  申请人：Luk Kin-Chun

  公开号：US20050256154A1

  公开（公告）日：2005-11-17

  Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon, lung and prostate. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer using these compounds.

  本文披露了一种新颖的4-氨基噻吩[3,2-c]吡啶-7-羧酸酰胺，以及它们的药用盐和酯，这些化合物是KDR和/或FGFR激酶的选择性抑制剂。这些化合物及其药用盐是抗增殖剂，可用于治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺的实体癌性肿瘤。还披露了含有这些化合物的药物组合物和使用这些化合物治疗癌症的方法。
• Substituted Thieno[3,2-C]Pyridine-7-Carboxylic Acid Derivatives
  申请人：Bartkovitz David Joseph

  公开号：US20080045562A1

  公开（公告）日：2008-02-21

  There are provided compounds of the formula wherein R 1 , R 2 , R 3 , X, Y, Q, Ring A and Ring B are as described. The compounds exhibit activity as anticancer agents.

  提供了具有以下结构的化合物，其中R1、R2、R3、X、Y、Q、环A和环B如所述。这些化合物表现出抗癌剂的活性。
• 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES
  申请人：Luk Kin-Chun

  公开号：US20110071147A1

  公开（公告）日：2011-03-24

  Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon, lung and prostate. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer using these compounds.

  本发明涉及新颖的4-氨基噻吩[3,2-c]吡啶-7-羧酸酰胺及其药学上可接受的盐和酯，它们是选择性抑制KDR和/或FGFR激酶的抑制剂。这些化合物及其药学上可接受的盐是抗增殖剂，可用于治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺的实体癌肿。本发明还涉及含有这些化合物的制药组合物和使用这些化合物治疗癌症的方法。
• Identification through structure-based methods of a bacterial NAD+-dependent DNA ligase inhibitor that avoids known resistance mutations
  作者：Kerry Murphy-Benenato、Hongming Wang、Helen M. McGuire、Hajnalka E. Davis、Ning Gao、D. Bryan Prince、Haris Jahic、Suzanne S. Stokes、P. Ann Boriack-Sjodin

  DOI：10.1016/j.bmcl.2013.11.007

  日期：2014.1

  In an attempt to identify novel inhibitors of NAD(+)-dependent DNA ligase (LigA) that are not affected by a known resistance mutation in the adenosine binding pocket, a detailed analysis of the binding sites of a variety of bacterial ligases was performed. This analysis revealed several similarities to the adenine binding region of kinases, which enabled a virtual screen of known kinase inhibitors. From this screen, a thienopyridine scaffold was identified that was shown to inhibit bacterial ligase. Further characterization through structure and enzymology revealed the compound was not affected by a previously disclosed resistance mutation in Streptococcus pneumoniae LigA, Leu75Phe. A subsequent medicinal chemistry program identified substitutions that resulted in an inhibitor with moderate activity across various Gram-positive bacterial LigA enzymes. (C) 2013 Elsevier Ltd. All rights reserved.
• 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1926737A1

  公开（公告）日：2008-06-04